SU11657 Enhances Radiosensitivity of Human Meningioma Cells

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 4, 2008, Pages 1213-1218

  Milker Zabel, Stefanie ^a   Bois, Angelika Zabel du ^a   Ranai, Gholamreza ^a   Trinh, Thuy ^a,b   Unterberg, Andreas ^a   Debus, Jürgen ^a   Lipson, Kenneth E ^c   Abdollahi, Amir ^a,b   Huber, Peter E ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c 3M COMPANY   (United States)

Author keywords

Angiogenesis; Meningioma; Radiotherapy; Receptor tyrosine kinase inhibitors; Sunitinib; VEGF PDGF

Indexed keywords

HUMAN MENINGIOMA CELLS; RADIOSENSITIVITY;

ENZYME ACTIVITY; IRRADIATION; NEUROSURGERY; RADIOTHERAPY; TUMORS;

CELL PROLIFERATION;

PROTEIN TYROSINE KINASE INHIBITOR; SU 11657; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MENINGIOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; UMBILICAL VEIN;

CELL MIGRATION ASSAYS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM PROTEINS; ORGANIC CHEMICALS; RADIATION TOLERANCE; RECEPTOR PROTEIN-TYROSINE KINASES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 39749090543     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.11.041     Document Type: Article

References (29)

1. Rachlin J.R. Etiology and biology of meningiomas. In: Al-Mefty O. (Ed). Meningiomas (1991), Raven Press, New York 27-35
2. Russel D.S., and Rubenstein L.J. Pathology of tumors of the central nervous system. 4th ed. (1995), Edward Arnold, London p. 66-91
3. Miralbell R., Linggood R.M., and de la Monte S. The role of radiation therapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13 (1992) 157-164
4. Bitzer M., Wockel L., Luft A.R., et al. The importance of pial blood supply to the development of peritumoral brain edema in meningioma. J Neurosurg 87 (1997) 368-373
5. Goldman C.K., Bharara S., Palmer C.A., et al. Brain edema in meningiomas is associated with increased vascular endothelia growth factor expression. Neurosurgery 40 (1997) 1269-1277
6. Abdollahi A., Lipson K.E., Skell A., et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced angiogenetic and antitumor effects. Cancer Res 63 (2003) 8890-8898
7. Colevas A.D., Brown J.M., Hahn S., et al. Development of investigational radiation modifiers. J Natl Cancer Inst 95 (2003) 46-51
8. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
9. Lantos P.L., VandenBerg S.R., and Kleihues P. Tumours of the central nervous system. In: Graham D.I., and Lantos P.L. (Eds). Greenfields neuropathology. 6th ed. (1997), Arnold, London 583-795
10. Louis D.N., Budka H., and von Deimling A. Meningiomas. In: Kleihues P., and Cavenee W.K. (Eds). Pathology and genetics of tumours of the nervous system (1997), International Agency for Research on Cancer, Lyon 134-141
11. Abdollahi A., Griggs D., Lipson K.E., et al. Inhibition of integrin survival signalling enhances antiangiogenetic and antitumor response of radiation. Clin Cancer Res 11 (2005) 6270-6279
12. Abdollahi A., Hlatky L., and Huber P.E. Endostatin: The logic of antiangiogenic therapy. Drug Resist Update 8 (2005) 59-63
13. Abdollahi A., Li M., Ping G., et al. Inhibition of platelet-derived growth factor signaling attenuated pulmonary fibrosis. J Exp Med 201 (2005) 925-935
14. Abdollahi A., Lipson K.E., Han X., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63 (2003) 3755-3763
15. Bischof M., Abdollahi A., Gong P., et al. Triple combination of irradiation chemotherapy (pemetrexed), and VEGFR2 inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 60 (2004) 1220-1232
16. Huber P.E., Bischof M., Jenne J., et al. Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65 (2005) 3643-3655
17. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
18. Oertel S., Krempien R., Lindel K., et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec©). Strahlenther Onkol 182 (2006) 400-407
19. O'Farrell A.M., Foran J.M., Fiedler W., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU1148 in acute myeloid leukaemia patients. Clin Cancer Res 9 (2003) 5465-5476
20. Schuenemann A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 (2003) 4009-4016
21. Sohal J., Phan V.T., Chan P.V., et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101 (2003) 3188-3197
22. Verheul H.M., and Pinedo H.M. Vascular endothelial growth factor and its inhibitors. Drug Today (Barc) 39 Suppl. C (2003) 81-93
23. Teicher B.A., Holden S.A., Ara G., et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 2 (1995) 269-276
24. Socinsci M.A., Novello S., and Sanchez J.M. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. J Clin Oncol 24 18S (2006) 7001
25. Fabian M.A., Biggs III W.H., Treiber D.K., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23 (2005) 329-336
26. Bäckman U., and Christofferson R. The selective class III/IV receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res 57 (2005) 690-695
27. Milker-Zabel S., Zabel A., Schulz-Ertner D., et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningiomas-Long term experience and prognostic factors. Int J Radiat Oncol Biol Phys 61 (2005) 810-817
28. Dziuk T.W., Woo S., Butler E.B., et al. Malignant meningioma: An indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 37 (1998) 177-188
29. Milosevic M., Frost P.J., Laperriere N.J., et al. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 34 (1996) 817-822